Table 6.
Comparison of the ropinirole dose between Parkinson’s disease without and with EDS (following total LEDD stratification*)
| Without EDS (n = 288) | With EDS (n = 125) | p value | |
|---|---|---|---|
| Group 1 | 0.009 | ||
| Cases | 96 | 41 | |
| Ropinirole (mg/d) | 5.5 ± 3.4 | 7.2 ± 3.8 | |
| Group 2 | 0.343 | ||
| Cases | 102 | 36 | |
| Ropinirole (mg/d) | 8.0 ± 5.2 | 8.9 ± 5.0 | |
| Group 3 | 0.357 | ||
| Cases | 90 | 48 | |
| Ropinirole (mg/d) | 11.4 ± 6.5 | 10.4 ± 5.2 |
*
groups were divided into three percentile categories of total LEDD: group 1 (n = 137, 487.2 ± 127.3 mg/d); group 2 (n = 138, 845.3 ± 109.6 mg/d); group 3 (n = 138, 1510.5 ± 444.9 mg/d).
EDS: excessive daytime sleepiness, LEDD: levodopa equivalent daily dose.